Skip to main content
SpringerLink
Log in

Platelet Surface Physiology and Its Importance in Pharmacotherapy Design and Development: The Adenosine Diphosphate Receptor Antagonists

  • Published:
Journal of Thrombosis and Thrombolysis Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. George JN. Studies on platelet plasma membranes: IV-Quantitative analysis of platelet membrane glycoproteins by (125I)-diazotized diiodosulfanilic acid labeling and SDS-polyacrylamide gel electrophoresis. J Lab Clin Med 1978;92:430-446.

    Google Scholar 

  2. Nurden AT, Caen JP. Membrane glycoproteins and human platelet function. Br J Haematol 1978;38: 155-160.

    Google Scholar 

  3. Phillips DR, Agin PP. Platelet membrane defects on Glanzmann's thromboasthenia. Evidence for decreased amounts of two major glycoproteins. J Clin Invest 1977;60:535-545.

    Google Scholar 

  4. Phillips DR, Agin PP. Platelet plasma membrane glycoproteins. Evidence for the presence of nonequivalent disulfide bonds using nonreduced-reduced two-dimensional gel electrophoresis. J Biol Chem 1977;252:2121-2126.

    Google Scholar 

  5. Plow EF, Ginsberg MH. The molecular basis of platelet function. In: Hoffman R, Benz EJ, Shaltil SJ, Furie B, Cohen HJ, eds. Hematology, Basic Principles and Practice, New York: Churchill Livingston 1991:1165.

    Google Scholar 

  6. Fauvel F, Grant ME, Legrand YJ, et al. Interaction of blood platelets with a microfibrillar extract from adult bovine aorta: Requirement for von Willebrand factor. Proc Natl Acad Sci U S A 1983;80:551-554.

    Google Scholar 

  7. Becker RC. Fibrinolytic and antithrombotic therapy: Therapy, Practice and management. Oxford University Press 2000. Oxford. pg. 38.

  8. Kinlough-Rathbone RL, Packham MA, Reimers HJ, Casenave JP, Mustard JF. Mechanisms of platelet shape change, aggregation, and release induced by collagen, thrombin, or A23, 187. J Lab Clin Med 1977;90:707-719.

    Google Scholar 

  9. Berridge MJ. Inositol triosephosphate and diacylglycerol: Two interacting second messengers. Ann Rev Biochem 1987;56:159-193.

    Google Scholar 

  10. Rink TJ, Sage SO. Calcium signaling in human platelets. Ann Rev Physiol 1990;52:431-449.

    Google Scholar 

  11. Stenberg PE, Shuman MA, Levine SP, Bainton DF. Redistribution of alpha-granules and their contents in thrombin-stimulated platelets. J Cell Biol 1984;98:748-760.

    Google Scholar 

  12. Ginsberg MH, Taylor L, Painter RG. The mechanism of thrombin-induced platelet factor 4 secretion. Blood 1980;55:661-668.

    Google Scholar 

  13. Van't Veer C, Hackeng TM, Delahaye C, Sixma JJ, Booma BN. Activated factor X and thrombin formation triggered by tissue factor on endothelial cell matrix in a flow model. Blood 1994;84:1132-1142

    Google Scholar 

  14. Gupta M, Doellgast GJ, Cheng T, Lewis JC. Expression and localization of tissue factor-based procoagulant activity in pigeon monocyte derived macrophages. Thromb Haemost 1993;70:963-969.

    Google Scholar 

  15. Hellem A. The adhesiveness of human blood platelets in vitro. Scand J Clin Invest 1960;12:1.

    Google Scholar 

  16. Gaarder A, Jonsen A, Laland S, Hellem AJ, Owren P. Adenosine diphosphate in red cells as a factor in the adhesiveness of human blood platelets. Nature 1961;192:531.

    Google Scholar 

  17. Burnstock G, Kennedy C. Is there a basis for distinguishing two types of P2 purinoceptors. Gen Pharmacol 1985;16:433-440.

    Google Scholar 

  18. Fredholm B, Abbracchio MP, Burnstock G, et al. Nomenclature and classification of purinoceptors. Pharmacol Rev 1994;46:143-156.

    Google Scholar 

  19. Abbracchio MP, Burnstock G. Purinoceptors: Are there three families of P2x and P2y purinoceptors? Pharmacol Ther 1994;64:445-475.

    Google Scholar 

  20. Nachman RL, Ferris B. Binding of adenosine diphosphate by isolated membranes from human platelets. J Biol Chem 1974;249:704-710.

    Google Scholar 

  21. Cattaneo M, Lecchi A, Randi AM, McGregor JL, Mannucci PM. Identification of a new congenital defect of platelet aggregation characterized by severe impairment of platelet responses to adenosine 5-diphosphate. Blood 192;80:2787-2796.

  22. Nurden P, Savi P, Heilmann E, et al. An inherited bleeding disorder linked to a defective interaction between ADP and its receptor on platelets. J Clin Invest 1995;95:1612-1622.

    Google Scholar 

  23. Altieri DC, Mannucci PM, Capitaneo AM. Binding of fibrinogen to human monocytes. J Clin Invest 1986;78:968-976.

    Google Scholar 

  24. Feolde E, Vigne P, Breittmayer JP, Frelin C. ATP, a partial agonist of atypical P2y purinoceptors in rat brain capillary endothelial cells. Br J Pharmacol 1995;115:1199-1203.

    Google Scholar 

  25. Humphries RG, Tomlinson W, Ingall AH, Cage PA, Leff P. FPL 66096: a novel, highly potent and selective antagonist at human platelet P2T-purinoceptors. Br J Pharmacol 1994;113:1057-1063.

    Google Scholar 

  26. Humphries RG; Tomlinson W, Clegg JA, Ingall AH, Kindon ND, Leff P. Pharmacological profile of the novel P2T-purinoceptor antagonist, FPL 67085 in vitro and in the anaesthetized rat in vivo. Br J Pharmacol 1995;115:1110-1116.

    Google Scholar 

  27. Clegg JA, Fraser-Rae L, Humphries RG, Robertson MJ. The effect of FPL 67085 on ADP-induced platelet aggregation ex vivo in the urethane-anaesthetized rat: A comparison with oral aspirin and ticlopidine. Br J Pharmacol 1995;114(suppl):102.

    Google Scholar 

  28. Bruno JJ. The mechanism of action of ticlopidine. Thromb Res 1983;4(suppl):59-67.

    Google Scholar 

  29. Piovella F, Ricetti MM, Almasioni P, et al. The effect of ticlopidine on human endothelial cells in culture. Thromb Res 1984;33:323-332.

    Google Scholar 

  30. O'Brien JR, Etherington MD, Shuttleworth RD. Ticlopidine antiplatelet drug: Effects in human volunteers. Thromb Res 1978;13:245-254.

    Google Scholar 

  31. Ellis DJ, Roe RL, Bruno JJ, et al. The effects of ticlopidine hydrochloride on bleeding platelet function in man. Thromb Haemost 1981;46:176. abstract.

    Google Scholar 

  32. De Caterina R, Sicari R, Bernini W, et al. Benefit/risk profile of combined antiplatelet therapy with ticlopidine and aspirin. Thromb Haemost 1991;65:504-510.

    Google Scholar 

  33. Di Minno G, Cerbone Am, Mattioli PL, et al. Functionally thromboasthenic state in normal platelets following the administration of ticlopidine. J Clin Invest 1985;75:328-338.

    Google Scholar 

  34. Panak E, Blanchard J, Roe RL. Evaluation of the antithrombotic efficacy of ticlopidine in man. Agents and actions supplements, ticlopidine. Haemostasis 1984;15:148-166.

    Google Scholar 

  35. Steinhubl SR, Tan WA, Foody JM, Topol EJ, for the EPISTENT Investigators. Incidence and clinical course of thrombotic thrombocytopenic purpura due to ticlopidine following coronary stenting. JAMA 1999;281:806.

    Google Scholar 

  36. Bennett CL, Weinberg PD, Rozenberg-Ben-Dror K, et al. Thrombotic thrombocytopenic purpura associated with ticlopidine. Ann Intern Med 1998;128:541-544.

    Google Scholar 

  37. Berglund U, von Schenck H, Wallentin L. Effects of ticlopidine on platelet function in men with stable angina pectoris. Thromb Haemost 1985;54:808-812.

    Google Scholar 

  38. Berglund U, Lassvik C, Wallentin L. Effects of platelet inhibitor ticlopidine on exercise tolerance in stable angina pectoris. Eur Heart J 1987;8:25-30.

    Google Scholar 

  39. Balsano F, Rizzon P, Violi F, et al. Antiplatelet treatment with ticlopidine in unstable angina. Circulation 1990;82:17-26.

    Google Scholar 

  40. Knudsen JB, Kjoller E, Skagen K, et al. The effect of ticlopidine on platelet functions in acute myocardial infarction: A double blind controlled trial. Thromb Haemost 1985;53;332-336.

    Google Scholar 

  41. Limet R, David J-L, Magotteaux P, et al. Prevention of aorta-coronary bypass graft occlusion. J Thorac Cardiovasc Surg 1987;94:773-783.

    Google Scholar 

  42. Sigwart U, Puel J, Mirkovitch V, et al. Intravascular stents to prevent occlusion and restenosis after transluminal angioplasty. N Engl J Med 1987;316:701-706.

    Google Scholar 

  43. Morice MC, Zemour G, Benviste E, et al. Intracoronary stenting without coumadin: One month results of a French multicenter study. Cathet Cardiovasc Diagn 1995;351:1-7.

    Google Scholar 

  44. Karrillon GJ, Morice MC, Benveniste E, et al. Intracoronary stent implantation without ultrasound guidance and with replacement of conventional anticoagulation by antiplatelet therapy: 30-day clinical outcome of the French Multicenter Registry. Circulation 1996;94:1519-1527.

    Google Scholar 

  45. Schömig A, Neumann F-J, Kastrati A, et al. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. N Engl J Med 1996;334:1084-1089.

    Google Scholar 

  46. Leon MB, Baim DS, Gordon P, et al. Clinical and angiographic results from the stent anticoagulation regimen study (STARS). Circulation 1996;94(suppl I):I-685.

    Google Scholar 

  47. Bertrand ME, Legrand V, Boland J, et al. Randomized multicenter comparison of conventional anticoagulation versus antiplatelet therapy in unplanned and elective coronary stenting. Circulation 1998;98:1597-1603.

    Google Scholar 

  48. Urban P, Macaya C, Rupprecht H-J for the MATTIS Investigators. Randomized evaluation of anticoagulation versus antiplatelet therapy after coronary stent implantation in high risk patients. Circulation 1998;98:2126-2132.

    Google Scholar 

  49. Rupprecht HJ, Darius H, Borkowski U, et al. Comparison of antiplatelet effects on aspirin, ticlopidine, or their combination after stent implantation. Circulation 1998;97:1046-1052.

    Google Scholar 

  50. Arcan JC, Blanchard J, Boissel JP, et al. Multicenter double-blind study of ticlopidine in the treatment of intermittent claudication and the prevention of its complications. J Vasc Dis 1988;September:802-811.

    Google Scholar 

  51. Janzon L, Bergquist D, Boberg J, et al. Prevention of myocardial infarction and stroke in patients with intermittent claudication: Effects of ticlopidine; results from STIMS, the Swedish ticlopidine multicenter study. J Intern Med 1990;227:301-308.

    Google Scholar 

  52. Gent M, Blakely JA, Easton JD, et al. The Canadian-American ticlopidine study (CATS) in thromboembolic stroke. Lancet 1989;1:1215-1220.

    Google Scholar 

  53. Hass WK, Easton JD, Adams HP, et al. A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high risk patients. N Engl J Med 1989;321:501-507.

    Google Scholar 

  54. Gachet C, Stierlé A, Cazenave JP, et al. The thienopyridine PCR 4099 selectively inhibits ADP-induced platelet aggregation and fibrinogen binding without modifying the membrane glycoprotein IIb-IIIa complex in rat and in man. Biochem Pharmacol 1990;40:229-238.

    Google Scholar 

  55. Gachet C, Savi P, Ohlmann P, et al. ADP receptor induced activation of guanine nucleotide binding proteins in rat platelet membranes – an effect selectively blocked by the thienopyridine clopidogrel. Thromb Haemost 1992;68:79-83.

    Google Scholar 

  56. Mills DCB, Puri R, Hu CJ, et al. Clopidogrel inhibits the binding of ADP analogues to the receptor mediating inhibition of platelet adenylate cyclase. Arterioscer Thromb 1992;12:430-436.

    Google Scholar 

  57. Savi P, Herbert JM, Pfieger AM, et al. Importance of hepatic metabolism in the antiaggregating activity of the thienopyridine clopidogrel. Biochem Pharmacol 1992;44:527-532.

    Google Scholar 

  58. Geiger J, Brich J, Hönig-Liedl P, et al. Specific impairment of human platelet P2YAC ADP receptor-mediated signaling by the antiplatelet drug clopidogrel. Arterioscler Thromb Vasc Biol 1999;19:2007-2011.

    Google Scholar 

  59. Combalbert J, Savi P, Rouchon MC, et al. Influence of hepatic cytochrome P450 subfamilies induction of antiaggregating activity and microsomal hepatic metabolism of the thienopyridine clopidogrel SR 25990C. XIIIth European Workshop of Drug Metabolism. September 21-25 1992. Bergamo, Italy.

  60. Anti-Platelet Trialists Collaboration. Secondary prevention of vascular disease by prolonged antiplatelet therapy. B M J 1988;296:320-331.

    Google Scholar 

  61. Boneu B, Destelle G on behalf of the Study Group. Platelet anti-aggregating activity and tolerance of clopidogrel in atherosclerotic patients. Thromb Haemost 1996;76:939-943.

    Google Scholar 

  62. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996;348:1329-1339.

    Google Scholar 

  63. Bertrand M. The Classics Trial: Classics. Circulation 1999;100:572.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Cardiovascular Thrombosis Research Center, University of Massachusetts Medical School, Worcester, Massachusetts

    Richard C. Becker

Authors
  1. Richard C. Becker
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Becker, R.C. Platelet Surface Physiology and Its Importance in Pharmacotherapy Design and Development: The Adenosine Diphosphate Receptor Antagonists. J Thromb Thrombolysis 10, 35–53 (2000). https://doi.org/10.1023/A:1018746704471

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1018746704471

Search

Navigation